Health Effects of Resveratrol: Results from Human Intervention Trials
Authors:
- Sonia L. Ramírez-GarzaSRSonia L. Ramírez-Garza
- Emily P. Laveriano-SantosELEmily P. Laveriano-Santos
- María Marhuenda-MuñozMaría Marhuenda-Muñoz
- Carolina E. StornioloCSCarolina E. Storniolo
- Anna Tresserra-RimbauATAnna Tresserra-Rimbau
- Anna Vallverdú-QueraltAnna Vallverdú-Queralt
- Rosa M. Lamuela-RaventósRosa M. Lamuela-Raventós
Open Access
Abstract
The effect of resveratrol (RV) intake has been reviewed in several studies performed in humans with different health status. The purpose of this review is to summarize the results of clinical trials of the last decade, in which RV was determined in biological samples such as human plasma, urine, and feces. The topics covered include RV bioavailability, pharmacokinetics, effects on cardiovascular diseases, cognitive diseases, cancer, type 2 diabetes (T2D), oxidative stress, and inflammation states. The overview of the recent research reveals a clear tendency to identify RV in plasma, showing that its supplementation is safe. Furthermore, RV bioavailability depends on several factors such as dose, associated food matrix, or time of ingestion. Notably, enterohepatic recirculation of RV has been observed, and RV is largely excreted in the urine within the first four hours after consumption. Much of the research on RV in the last 10 years has focused on its effects on pathologies related to oxidative stress, inflammatory biomarkers, T2D, cardiovascular diseases, and neurological diseases.Keywords
Funding Information
- Ministerio de Ciencia, Innovación y Universidades (AGL2016-75329-R)
- Generalitat de Catalunya (2017 SGR 196)
- Instituto de Salud Carlos III (CIBEROBN CB12/03/30020)
This publication has 67 references indexed in Scilit:
- Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic DiseasesAntioxidants & Redox Signaling, 2013
- Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and PharmacodynamicsCancer Prevention Research, 2011
- Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor AxisCancer Research, 2010
- Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous MiceThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2010
- An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approachThe American Journal of Clinical Nutrition, 2010
- Resveratrol Delays Age-Related Deterioration and Mimics Transcriptional Aspects of Dietary Restriction without Extending Life SpanCell Metabolism, 2008
- A Low Dose of Dietary Resveratrol Partially Mimics Caloric Restriction and Retards Aging Parameters in MicePLOS ONE, 2008
- SIRT1 transgenic mice show phenotypes resembling calorie restrictionAging Cell, 2007
- Resveratrol improves health and survival of mice on a high-calorie dietNature, 2006
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006